Skip to main content
Clinical Trials/NCT01688323
NCT01688323
Completed
Not Applicable

Identification of Predictors of Tolerance to Chemoradiotherapy in Elderly Patients With Head and Neck Cancer

UNC Lineberger Comprehensive Cancer Center1 site in 1 country3 target enrollmentJuly 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Head and Neck Cancer
Sponsor
UNC Lineberger Comprehensive Cancer Center
Enrollment
3
Locations
1
Primary Endpoint
Significant Change in Function from Baseline to Post-Treatment
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

To look at what types of measures can be used to predict how an older person will tolerate chemoradiation treatment for head and neck cancer. This study uses surveys and a blood draw to look at the different measures.

Detailed Description

Purpose: To identify baseline predictors of change in function over the course of treatment with chemoradiotherapy in patients with head and neck cancer. Participants: Patients 65 or older who have an appointment at the North Carolina Cancer Hospital (NCCH) or other participating sites, have planned chemoradiotherapy for head and neck cancer Procedures (methods): Consenting subjects will complete a Geriatric Assessment, Functional Assessment of Cancer Therapy - Head and Neck and give a blood sample for CBC and p16INK4a at the start of their chemoradiotherapy, at week four, at the end and 90 days post therapy. They will also complete a health behavior questionnaire at baseline.

Registry
clinicaltrials.gov
Start Date
July 2012
End Date
May 2016
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Significant Change in Function from Baseline to Post-Treatment

Time Frame: 2 years

To determine if there is a significant change in the Instrumental Activities of Daily Living (IADL) subscore of the Geriatric Assessment (GA) from baseline to 90 days post-treatment.

Secondary Outcomes

  • Explore Association of Baseline Measures with Grade 3 or Higher Toxicity(2 years)
  • Explore Association of Baseline p16 with Baseline GA Measures(2 years)
  • Explore Association between Baseline Measures and Decline in Living Status(2 years)
  • Explore Changes in p16 Expression, GA Subscales and FACT-HN Scores Over Time.(2 years)
  • Explore Association between Baseline Measures and Changes in IADL Subscore(2 years)

Study Sites (1)

Loading locations...

Similar Trials